RT Journal Article
SR Electronic
T1 Defective monocyte enzymatic function and an inhibitory immune phenotype in HIV-exposed uninfected African infants in the era of anti-retroviral therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.26.21261143
DO 10.1101/2021.07.26.21261143
A1 Afran, Louise
A1 Jambo, Kondwani C.
A1 Nedi, Wilfred
A1 Miles, David JC
A1 Kiran, Anmol
A1 Banda, Dominic H
A1 Kamg’ona, Ralph
A1 Tembo, Dumizulu
A1 Burger, Annette
A1 Nastouli, Eleni
A1 Ferne, Brigit
A1 Mwandumba, Henry C
A1 Moss, Paul
A1 Goldblatt, David
A1 Rowland-Jones, Sarah
A1 Finn, Adam
A1 Heyderman, Robert S
YR 2021
UL http://medrxiv.org/content/early/2021/07/30/2021.07.26.21261143.abstract
AB HIV-Exposed Uninfected (HEU) infants are a rapidly expanding population in sub-Saharan Africa and are highly susceptible to disease caused by encapsulated bacteria in the first year of life. The mechanism of this increased risk is still poorly understood. We therefore investigated if HIV exposure dysregulates HEU infant immunity and if this is amplified by human herpes virus infection (HHV). Here, we compared monocyte enzymatic function, innate and adaptive immune cell phenotype, and vaccine-induced antibody responses between HEU and HUU infants. We demonstrate altered monocyte phagosomal function and B cell subset homeostasis, and lower vaccine-induced anti-Haemophilus influenzae type b (Hib) and anti-Tetanus Toxoid (TT) IgG titers in HEU compared to HUU infants. There was no difference in the prevalence of HHV infection between HEU and HUU infants. Our findings suggest that even in the era of antiretroviral therapy (ART)-mediated viral suppression, HIV exposure dysregulates monocyte and B cell function during a vulnerable period of immune maturation in infancy. This may contribute to the high rates of invasive bacterial disease and pneumonia in HEU infants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a studentship from the Franklin Adams Trust and a project grant from the Wellcome Trust. The Malawi-Liverpool-Wellcome Trust Clinical Research Programme was supported by a strategic award from the Wellcome Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was performed in Malawi. Written informed consent was obtained from all participants prior to recruitment. Ethical approval was obtained from the University of Malawi College of Medicine Research and ethics committee (COMREC), Blantyre, Malawi, protocol numbers 319 P.11/11/1140, P.06/11/1088.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is not available.